Royalty Pharma plc Proceeds from Sale of Debt Securities, Available-for-sale
Royalty Pharma plc (RPRX) reported Proceeds from Sale of Debt Securities, Available-for-sale of $8.64 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt · last filed 2026-08-05
- Royalty Pharma plc proceeds from sale of debt securities, available-for-sale for the quarter ending 2026-06-30 was $4.32M, a 50.00% increase year-over-year.
- Royalty Pharma plc proceeds from sale of debt securities, available-for-sale for the quarter ending 2026-03-31 was $4.32M, a 65.68% decline year-over-year.
- Royalty Pharma plc proceeds from sale of debt securities, available-for-sale for the quarter ending 2025-12-31 was $2.88M, a 77.12% decline year-over-year.
- Royalty Pharma plc proceeds from sale of debt securities, available-for-sale for the quarter ending 2025-09-30 was $2.88M, a 0.00% change year-over-year.
- Royalty Pharma plc proceeds from sale of debt securities, available-for-sale for fiscal 2025 was $21.23M, a 7.28% increase from fiscal 2024.
- Royalty Pharma plc proceeds from sale of debt securities, available-for-sale for fiscal 2024 was $19.79M, a 1274.03% increase from fiscal 2023.
- Royalty Pharma plc proceeds from sale of debt securities, available-for-sale for fiscal 2023 was $1.44M, a 99.73% decline from fiscal 2022.
- Royalty Pharma plc proceeds from sale of debt securities, available-for-sale for fiscal 2022 was $542.04M, a 767.27% increase from fiscal 2021.
| Period end | Proceeds from Sale of Debt Securities, Available-for-sale 3 month | Proceeds from Sale of Debt Securities, Available-for-sale 6 month | Proceeds from Sale of Debt Securities, Available-for-sale 9 month | Proceeds from Sale of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $8.64M 10-Q · filed 2026-08-05 | $11.52M derived: sum of 3 quarters · filed 2026-08-05 | $14.40M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $4.32M 10-Q · filed 2026-05-06 | $7.20M derived: sum of 2 quarters · filed 2026-05-06 | $10.08M derived: sum of 3 quarters · filed 2026-05-06 | $12.96M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $2.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $5.76M derived: sum of 2 quarters · filed 2026-02-11 | $8.64M derived: sum of 3 quarters · filed 2026-08-05 | $21.23M 10-K · filed 2026-02-11 |
| 2025-09-30 | $2.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $5.76M derived: sum of 2 quarters · filed 2026-08-05 | $18.35M 10-Q · filed 2025-11-05 | $30.93M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $2.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $15.47M 10-Q · filed 2026-08-05 | $28.05M derived: sum of 3 quarters · filed 2026-08-05 | $30.93M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $12.59M 10-Q · filed 2026-05-06 | $25.17M derived: sum of 2 quarters · filed 2026-05-06 | $28.05M derived: sum of 3 quarters · filed 2026-05-06 | $30.93M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $12.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $15.47M derived: sum of 2 quarters · filed 2026-02-11 | $18.35M derived: sum of 3 quarters · filed 2026-02-11 | $19.79M 10-K · filed 2026-02-11 |
| 2024-09-30 | $2.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $5.76M derived: sum of 2 quarters · filed 2025-11-05 | $7.20M 10-Q · filed 2025-11-05 | $8.64M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $2.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $4.32M 10-Q · filed 2025-08-06 | $5.76M derived: sum of 3 quarters · filed 2026-02-11 | $5.76M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $1.44M 10-Q · filed 2025-05-08 | $2.88M derived: sum of 2 quarters · filed 2026-02-11 | $2.88M derived: sum of 3 quarters · filed 2026-02-11 | $2.88M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.44M derived: sum of 2 quarters · filed 2026-02-11 | $1.44M derived: sum of 3 quarters · filed 2026-02-11 | $1.44M 10-K · filed 2026-02-11 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | $495.17M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | $495.17M derived: sum of 3 quarters · filed 2025-02-12 | $510.79M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 | $495.17M derived: sum of 2 quarters · filed 2025-02-12 | $510.79M derived: sum of 3 quarters · filed 2025-02-12 | $526.42M derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | $495.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $510.79M derived: sum of 2 quarters · filed 2025-02-12 | $526.42M derived: sum of 3 quarters · filed 2025-02-12 | $542.04M 10-K · filed 2025-02-12 |
| 2022-09-30 | $15.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $31.25M derived: sum of 2 quarters · filed 2023-11-08 | $46.88M 10-Q · filed 2023-11-08 | $62.50M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $15.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $31.25M 10-Q · filed 2023-08-08 | $46.88M derived: sum of 3 quarters · filed 2024-02-15 | $62.50M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $15.63M 10-Q · filed 2023-05-09 | $31.25M derived: sum of 2 quarters · filed 2024-02-15 | $46.88M derived: sum of 3 quarters · filed 2024-02-15 | $62.50M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $15.63M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $31.25M derived: sum of 2 quarters · filed 2024-02-15 | $46.88M derived: sum of 3 quarters · filed 2024-02-15 | $62.50M 10-K · filed 2024-02-15 |
| 2021-09-30 | $15.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $31.25M derived: sum of 2 quarters · filed 2022-11-08 | $46.88M 10-Q · filed 2022-11-08 | $49.88M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | $15.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $31.25M 10-Q · filed 2022-08-04 | $34.25M derived: sum of 3 quarters · filed 2023-02-15 | $34.25M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | $15.63M 10-Q · filed 2022-05-05 | $18.63M derived: sum of 2 quarters · filed 2023-02-15 | $18.63M derived: sum of 3 quarters · filed 2023-02-15 | $18.63M derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $3.00M derived: sum of 2 quarters · filed 2023-02-15 | $3.00M derived: sum of 3 quarters · filed 2023-02-15 | $3.00M 10-K · filed 2023-02-15 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | $0.00 derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $0.00 10-Q · filed 2021-08-11 | $0.00 derived: sum of 3 quarters · filed 2022-02-15 | $0.00 derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-11 | $0.00 derived: sum of 2 quarters · filed 2022-02-15 | $0.00 derived: sum of 3 quarters · filed 2022-02-15 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $0.00 derived: sum of 2 quarters · filed 2022-02-15 | $150.00M 10-K · filed 2022-02-15 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $150.00M 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $150.00M 10-Q · filed 2020-08-12 | |||
| 2018-12-31 | $750.00M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |